Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


In a cohort of more than 400,000 patients at high risk for CVD requiring primary prevention, less than half were taking appropriately dosed statins and less than 10% were taking nonstatin lipid-lowering therapies, researchers reported. For an abstract presented at the National Lipid Association Scientific Sessions, Ahmed A. Kolkailah, MD, cardiovascular medicine fellow at the University of Texas